Article Sidebar
Published:
Jul 9, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Azadiradione exerts anti-inflammatory and anti-oxidant effects, alleviates dopaminergic neurodegeneration and reduces α-synuclein levels in MPTP-induced mouse model of Parkinson’s disease
Abstract
Purpose: To determine the effects of azadiradione (AZD), a tetracyclic triterpenoid, in 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)–induced experimental rodent model of Parkinson’s disease (PD).
Methods: C57BL/6 mice were intraperitoneally injected MPTP at a dose of 20 mg/kg body weight in saline (4 times at 2-h intervals). Azadiradione (AZD) at doses of 12.5, 25 or 50 mg/kg were administered to separate groups of mice via oral gavage for 6 days prior to MPTP injection.
Results: Azadiradione (AZD) reduced loss of tyrosine hydroxylase (TH)-positive neurons. TH-positive counts increased to 91.44 % on treatment with 50 mg/kg AZD. Significantly (p < 0.05) down-regulated α-synuclein levels were seen following MPTP induction and AZD administration. Expressions of Bax, Bcl-2 and cleaved-caspase-3 were significantly downregulated (p < 0.05). Treatment with AZD inhibited the translocation of Cyt-C to the mitochondria, thereby preventing activation of apoptotic cascade. Oxidative stress induced by MPTP was significantly reduced by AZD via up-regulation of glutathione levels and SOD1/HO-1 expression. Azadiradione, at a dose of 50 mg/kg, significantly (p < 0.05) reduced ROS levels from 210.6 19.23%, and also reduced the levels of inflammatory cytokines.
Conclusion: These results indicate the anti-inflammatory, anti-oxidative and neuroprotective properties of AZD in mice. Thus, AZD is a potential candidate drug for the management of PD. However, further studies are required to ascertain this.
